Related Experiment Video
Updated: Jan 16, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Delayed-Onset ICI-Associated Myocarditis: When Immunotherapy's Cardiac Consequences Outlast Treatment
Fadi W Adel1, Ghasaq Saleh1, Nandan S Anavekar1
1Department of Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
Immune checkpoint inhibitor (ICI) myocarditis is a rare but serious side effect of cancer therapy. Early diagnosis using advanced imaging and biopsy, followed by prompt corticosteroid treatment, is crucial for patient survival.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are vital cancer therapies.
- ICIs can cause immune-related adverse events, including potentially fatal myocarditis.
- Myocarditis presents a diagnostic challenge, mimicking other cardiac conditions.
More Related Videos
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis IV: Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy